Monte Rosa Therapeutics (GLUE) Income from Continuing Operations (2020 - 2026)
Monte Rosa Therapeutics (GLUE) recorded quarterly Income from Continuing Operations of 44503000.0 in Q1 2026, down 50.91% quarter-over-quarter from 29489000.0 in Q4 2025, and down 194.92% on a YoY basis from 46885000.0 in Q1 2025.
Monte Rosa Therapeutics (GLUE) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Monte Rosa Therapeutics' Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 44503000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 194.92% year-over-year to 44503000.0; the TTM figure through Mar 2026 stood at 113368000.0 (down 1942.48% YoY), while the FY2025 annual figure was 21980000.0, up 69.77% from the prior year.
- Income from Continuing Operations was 44503000.0 for Q1 2026 at Monte Rosa Therapeutics, down from 29489000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 46885000.0 in Q1 2025 to a low of 44503000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 22544529.41 across 5 years, with a median of 29489000.0 in 2025.
- Biggest YoY gain for Income from Continuing Operations was 246.66% in 2025; the steepest drop was 319.46% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 30782000.0 in 2022, then decreased by 8.02% to 33252000.0 in 2023, then surged by 140.41% to 13437000.0 in 2024, then plunged by 319.46% to 29489000.0 in 2025, then slumped by 50.91% to 44503000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 44503000.0 (Q1 2026), 29489000.0 (Q4 2025), and 27081000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Monte Rosa Therapeutics | 1.83 Bn | 1.15 Bn | - | -44.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -44.50 Mn |
| Dec 31, 2025 | -29.49 Mn |
| Sep 30, 2025 | -27.08 Mn |
| Jun 30, 2025 | -12.30 Mn |
| Mar 31, 2025 | 46.89 Mn |
| Dec 31, 2024 | 13.44 Mn |
| Sep 30, 2024 | -23.86 Mn |
| Jun 30, 2024 | -30.31 Mn |
| Mar 31, 2024 | -31.97 Mn |
| Dec 31, 2023 | -33.25 Mn |
| Sep 30, 2023 | -34.88 Mn |
| Jun 30, 2023 | -35.18 Mn |
| Mar 31, 2023 | -32.04 Mn |
| Dec 31, 2022 | -30.78 Mn |
| Sep 30, 2022 | -27.32 Mn |
| Jun 30, 2022 | -26.47 Mn |
| Mar 31, 2022 | -24.15 Mn |
| Dec 31, 2021 | -23.37 Mn |
| Sep 30, 2021 | -19.86 Mn |
| Jun 30, 2021 | -18.11 Mn |